Here's some local Houston startup news you may have missed. Photo by Zview/Getty Images

Houston startups across industries have been moving and shaking these past few weeks, and there's a chance you may have missed some of these Houston innovation stories.

In this roundup of short stories within Houston innovation, two Houston-based e-commerce startups announce big news, a tech company pitches abroad, and more.

Houston industrial e-commerce startup expands into the construction industry

Houston-based GoExpedi has expanded its business. Photo by Colt Melrose for GoExpedi

GoExpedi, an end-to-end digital supply chain and data analytics company with solutions within procurement and delivery of maintenance, repair, and operations products for heavy industries, announced it has expanded into the commercial construction space.

Builders partnering with GoExpedi now have access to more than 200,000 critical parts and supplies, according to a news release from the company.

"Access to needed tools and materials in construction is already a challenge in today's supply chain environment," says GoExpedi CEO Tim Neal in the release. "Expanding into commercial construction is a natural extension of our capabilities as we already provide significant operational and cost value with our digital platform across similar heavy sectors. We're quickly ramping up the number of construction groups we're working with, giving them a better way to plan for and order materials to help avoid costly building delays."

GoExpedi raised a $25 million series C round in 2020 and is deploying these funds as the company grows. Earlier this year, the startup opened a new industrial and energy MRO warehouse in Pittsburgh, Pennsylvania

UH business college snags prestigious grant

Dean​ Paul Pavlou leads the University of Houston's Bauer College of Business.

The University of Houston's C. T. Bauer College of Business is partnering with Texas A&M University and Temple University to develop and implement an energy risk tracking and alert system in Houston and San Antonio. The research project recently received $1.5 million in grant funding from the National Science Foundation. The grant is part of the Smart and Connected Communities program.

"Advanced Learning for Energy Risk Tracking" (ALERT) is designed to prevent and mitigate costly and potentially devastating electricity outages — such as the 2021 winter storm — according to a news release from UH. Bauer College Dean and Cullen Distinguished Chair Professor Paul A. Pavlou is one of co-investigators.

"If there is one positive outcome of the winter storm, it certainly created an awareness for many people that we need to invest more in intelligent systems that can minimize the huge costs and negative impacts that electricity outages can have on people and local communities," he says in the release. "The idea of this research is to create a data-driven system to reduce, predict, and mitigate costly power outages, especially in traditionally disadvantaged communities that usually suffer the most from power outages."

The ALERT system depends on data generated by utilities, city and county governments, school districts and others, enabling preemptive repairs and allowing officials to react more quickly in the event of unforeseen outages, per the release, and a test version of the resource may begin operating in San Antonio as soon as 2022, followed by a trial in Houston.

"It's a technologically very advanced solution, but the beauty of it is that we are working with local communities to acquire the data, to enhance the system and also feed the data back to the community to actually minimize the impact on the people who suffer most from power outages," Pavlou says in the release.

Houston health tech company receives new investment

Dan Purvis, CEO of Velentium

A Houston company has fresh funding. Photo courtesy of Velentium

Velentium has announced a growth recapitalization in partnership with Connecticut-based Great Point Partners. Houston-based Velentium is an engineering firm specializing in the design and manufacturing of therapeutic and diagnostic active medical devices, and GPP is a leading health care investment firm. The new investment allows Velentium to scale national operations.

"When Great Point reached out to us earlier this year, we were immediately impressed with their deep knowledge of our market and track record building businesses," says Dan Purvis, CEO of Velentium, in a news release. "We continue to build an organization that improves the lives of people and families by helping to bring transformative medical devices to market, and Great Point is uniquely positioned to enable us to do that at an even larger scale. Today, we are starting a new chapter and taking a crucial step in realizing our dream of having 1,000 families as part of our organization."

Velentium was created to advance the next breakthrough medical device technology — all within the same company. Innovators and inventors don't have to go through the processes — from cybersecurity to manufacturing — by themselves.

"Our dream from day one was to create a one-stop shop here in Houston where new startups with IP can come to us and know that start to finish they would have their commercial device ready for approval with the FDA and that we were going to handle everything," Purvis previously told InnovationMap.

With GPP's investment, Velentium is equipped to augment its end-to-end solutions and its nearshore and offshore manufacturing capabilities, per the release.

"Velentium has played a pivotal role in the development of groundbreaking neuromodulation devices that have led to important medical technology advancements," says GPP Managing Director Adam Dolder in the release. "We look forward to being partners with Dan, Tim and the entire team and helping them to achieve their goals for the company."

Houston startup tapped for European pitch competition

Jessica Reitmeier, is the co-founder of Pandata Tech. Photo courtesy of Pandata Tech

Houston-based Pandata Tech is one of 29 companies from around the globe competing in Scotland's Net Zero Technology Centre's Clean Energy Start-up Pitch Battle finals. Each featured company has a technology solution that can help accelerate the transition to a net zero energy industry, and 10 finalists will be selected to pitch at COP 26 UN Climate Change Conference in Glasgow, Scotland, on November 2, 2021.

"These start-ups are truly inspiring. Offering extraordinary innovation and ambition, all these teams are developing technologies that have significant potential to reduce greenhouse gas emissions," says Mark Anderson, TechX Director of Net Zero Technology Centre.

The Ion Houston nominated Pandata Tech to be part of the competition because of the startup's previous work in offshore energy and geothermal utility distribution.

"When we think about reducing C02 emissions by 50 percent or more by 2030 and the data required to meet that mark, it's simple — humans and algorithms need data they can trust," says Jessica Reitmeier, co-founder of Pandata.

Houston e-commerce services provider announces strategic partnership

Houston-based e-commerce software startup and Amazon competitor raises $25M in its series A

Cart.com has a new partner, which has increased access to tools for its clients. Photo via cart.com

Houston-based Cart.com, an end-to-end ecommerce services provider and Amazon competitor, announced a strategic partnership with Clearco, the world's largest ecommerce investor. With the new partnership, Cart.com's clients will receive access to Clearco's capital financing and Clearco's portfolio of over 5,500 companies will have access to Cart.com's end-to-end e-commerce platform.

"We're committed to making all aspects of running an ecommerce business streamlined and hassle-free — and that includes getting access to the capital needed to fuel growth," says Omair Tariq, Cart.com CEO, in a news release. "Through this partnership we're giving online sellers frictionless access to the resources they need to scale up, while allowing founders to stay laser-focused on serving their customers and building their brand."

The two companies share the mission to democratize ecommerce by delivering easier, more streamlined access to critical resources — including capital, services, and domain-specific information — which have previously only been available to companies like Amazon.

"Like Cart.com, we envision a world where founding a business is accessible to everyone, and where founders can access essential capital without having to jump through endless hoops," says Andrew D'Souza, Clearco CEO, in the release. "By partnering with Cart.com, Clearco companies will be able to access the platform's end-to-end ecommerce engine — including online store technology, integrated fulfillment services, and customer service support — to scale their ecommerce growth."

This week's roundup of Houston innovators includes Dan Purvis of Velentium, Tony Sanchez of OneNexus Environmental, and Kevin Doffing of Energy Capital of the Future. Courtesy photos

3 Houston innovators to know this week

who's who

Keep reading...Show less
Dan Purvis, CEO and founder of Velentium, is leading his growing company with culture in mind. Photo courtesy of Velentium

Local tech exec expands med device company into oil and gas in a 'uniquely Houston' way

HOUSTON INNOVATORS PODCAST EPISODE 90

When asked about founding his company, the first thing Dan Purvis wants to talk about is the culture.

"The technology of today and the technology of 24 months from now will be very different," Purvis, CEO and founder of Houston-based Velentium, says on this week's episode of the Houston Innovators Podcast. "Being culture-forward allows us to make sure that the people we have on staff are able to flex with the industry."

Velentium was created to advance the next breakthrough medical device technology — all within the same company. Innovators and inventors don't have to go through the processes — from cybersecurity to manufacturing — by themselves.

"Our dream from day one was to create a one-stop shop here in Houston where new startups with IP can come to us and know that start to finish they would have their commercial device ready for approval with the FDA and that we were going to handle everything," Purvis explains.

These days, cybersecurity is top of mind for Velentium, as the technology Purvis and his team are working with include life and death situations. While IT and other software security is important, protecting patients using new medical devices is paramount.

"If you have a dog in your backyard and you have one hole in your fence, you're dog is going to get out," Purvis says."You can't have any holes in that fence. … Our design allows for that protection."

Following an acquisition of Magnolia, Texas-based Oasis Testing, a designer of automated test systems for the energy and manufacturing industries in January, Velentium has expanded to also work in oil and gas technology development. While completely different fields, Velentium says the entrance into this energy tech market has been smooth sailing.

"We really find that both sides of the company cross pollinate quite a bit, and I think that's something that's uniquely Houston," Purvis says.

He shares more about the expansion and how his company continues to grow on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

A new medical device created in Houston is revolutionizing opioid withdrawal treatment. Photo via sparkbiomedical.com

Houston med-tech companies partner on wearable device for opioid withdrawal

treating addiction

Houston-based Spark Biomedical has created a revolutionary wearable device that provides unprecedented levels of opioid withdrawal relief.

The device known as the Sparrow Therapy System is worn over the ear for five to seven days and sends mild electrical signals to trigger cranial nerves that sit near the skin's surface.

Once activated, the nerves release endorphins that the body has stopped producing on its own during opioid use. The endorphins satisfy the opioid receptors and in turn reduce or prevent the intense symptoms that often come along with opioid withdrawal. According to Spark BioMed CEO Daniel Powell, the technology also helps patients better control their "flight or fight mechanisms," allowing them to make clearer, more logical decisions as they come off of the drug.

"If you ask 100 people who've gone through opioid withdrawal, I would bet 99 of them will tell you they thought they were going to die," Powell says. "Giving them the ability to manage that is huge. It's the first step towards addiction recovery. It's not solving the addiction, but it is an absolute barrier to move forward."

The product was approved by the FDA in January of 2020, after clinical trials showed that the Sparrow could meaningfully reduce withdrawal symptoms in the first hour of use. According to Powell, roughly a third of patients in the trial were completely out of withdrawal and patients' Clinical Opioid Withdrawal Scales scores reduced by more than 53 percent across the board.

Spark, which won Venture Houston's inaugural pitch competition earlier this year, partnered with Houston-based Velentium (which also happened to grow 93 percent last year after partnering with General Motors on Project V) to bring the product from concept to commercial physician prescribed product. "We needed a more sophisticated design house to help us finish it," Powell says.

The up-and-comers were connected through one of Spark's investors. Powell, in a previous career, had also sold a neurostimulator that Velentium CTO Randy Armstrong had invented.

"You're seeing more and more Houston centric medical innovation than we've ever seen before," says Velentium CEO Dan Purvis. "And the cool thing about that is there ends up being a camaraderie amongst entrepreneurs, medical researchers and scientists."

And though the release of Sparrow marks a huge milestone, neither Spark of Velentium are stopping there. Moving forward, Spark aims to conduct a massive study on how a similar technology, dubbed the Roo, can aid infants born to opioid-dependent mothers wean from the drug.

The company also aims to create a next generation Sparrow with the help of Velentium, and will look at long-term uses of the product. Powell says that Spark will look to determine if the product can prevent relapses and help to cure addiction when worn daily or regularly.

"Our big, crazy, ambitious goal is can we actually help people recover from addiction," Powell says. "We're really not addressing psychology, that's going to be in cognitive behavioral therapy. But if we can remove the neurological results of drug use, we think we can make at least start to stack the deck in the favor of the patient versus having the deck stacked completely against them all the time."

This week's roundup of Houston innovators includes Niloufar Molavi of Central Houston Inc., Dan Purvis of Velentium, and Chris Staffel of Goose Capital. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In the week's roundup of Houston innovators to know, I'm introducing you to three innovators — each either new to their role or with a bit of acquistion news.

Niloufar Molavi, board chair at Central Houston Inc.

Niloufar Molavi will lead Central Houston Inc.'s board this year — and she's got fostering innovation on her to-do list. Photo courtesy of CHI

Last week, Nilofar Molavi assumed the role of board chair for Central Houston. She leads PwC's Global energy practice and has served on the CHI board since 2011 and chairs the organization's innovation committee. CHI was among the partners behind the Downtown Launchpad, a 17,000-square-foot innovation hub, which had its grand opening last fall.

"With the fall 2020 opening of Downtown Launchpad, we have deepened our investment in innovation, which we hope will garner long-term results and economic vitality for downtown as well as the Houston region at large," she continues. "We look forward to developing bridge programs with area universities and organizations and leveraging existing resources to bring more high-tech prospects to our central city." Read more.

Dan Purvis, CEO of Velentium

A Houston company has made a strategic acquisition. Photo courtesy of Velentium

Houston-based Velentium, which specializes in the design and manufacturing of medical devices announced that it has acquired Texas company Oasis Testing, a designer of automated test systems for the energy and manufacturing industries.

"Despite the immense challenges facing the business community in 2020, last year was a monumental year of growth for our firm, and we're pleased to start 2021 building upon our world-class team of technical experts," says Dan Purvis, CEO of Velentium, in a news release. "Oasis Testing has been a trusted partner for the last five years and shares in our commitment to solving clients' most complex challenges to change lives for a better world. We're incredibly excited to welcome them to the Velentium family and expand our business more deeply into energy and manufacturing."

Purvis will lead the new combined company as CEO. Read more.

Chris Staffel, managing director at Goose Capital

Goose Capital recently named its new managing director. Photo courtesy of Chris Staffel

Houston-based investment group Goose Capital Inc. named Chris Staffel as managing director — along with Jeff Smisek as the firm's president and Jay Collins as chair of the board of directors.

A serial entrepreneur and investor in over 30 startups, Staffel joins Goose to lead day-to-day operations and drive new investment opportunities.

"It is an honor to join the team at Goose Capital and work alongside experienced industry leaders," Staffel says in the release. "I look forward to leveraging my entrepreneurial experience to help the start-ups in which we invest, while strategically identifying early stage investment opportunities." Read more.

Dan Purvis, CEO of Velentium, will lead the new combined company. Photo courtesy of Veletium

Houston-area medical device engineering firm acquires Texas company

M&A

A engineering firm based in Katy has made a strategic acquisition of a Magnolia, Texas-based company to start of the new year.

Velentium, which specializes in the design and manufacturing of medical devices announced that it has acquired Oasis Testing, a designer of automated test systems for the energy and manufacturing industries.

"Despite the immense challenges facing the business community in 2020, last year was a monumental year of growth for our firm, and we're pleased to start 2021 building upon our world-class team of technical experts," says Dan Purvis, CEO of Velentium, in a news release. "Oasis Testing has been a trusted partner for the last five years and shares in our commitment to solving clients' most complex challenges to change lives for a better world. We're incredibly excited to welcome them to the Velentium family and expand our business more deeply into energy and manufacturing."

The companies will operate under the Velentium name, and Demetri White, co-founder at Oasis Testing, will assume the role of senior program manager to focus on "growing the testing business, serving the oil and gas industry's need for high-pressure high-temperature test, as well as testing in the medical device sector," according to the release.

"We admire and share Velentium's approach to client service, company culture, and results-focused business strategy, and quickly recognized this would be an excellent fit for our team," says White in the. "From our years of partnership, we know that Oasis' expertise in servicing the energy and manufacturing sectors goes hand-in-hand with their ability to provide innovative and world class solutions. Together, we will leverage knowledge across industries to bring mechanical, electrical and software-based solutions that benefit our client base."

The new company will have expanded abilities and will be increasing its production space and headcount as it continues to place an emphasis on its testing and manufacturing capabilities. The added resources for automation and the combined team will lead to dramatic reductions in product test times and increased test system utilization.

Earlier this year, Velentium played a key role in mobilizing thousands of ventilators in the United States at a time when the pandemic and the uncertainty around it was surmounting around the country.

The company's long-time clients Ventec Life Systems, a manufacturer of ventilators based in Washington, said they could increase production of their much-needed ventilators five-fold if they only had the right resources and partners. Velentium first aimed to help the small factory double or triple their production, and later General Motors jumped in to help grow the initiative.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.